Evidence map›Paper›PMID 42430493›Full record

ArticleScience advances2026

Modeling Parkinson's pathology in human iPSC dopaminergic neurons uncovers key mechanisms of Lewy body formation and heterogeneity.

Anne-Laure Mahul-Mellier, Lukas van den Heuvel, Maxime Teixeira, Manel L N Boussouf, Gaspard Oudinot, Amélie Thonet, Davide Speri, Yllza Jasiqi, Christina Ulrich, Razan Sheta and 7 more

Abstract read
In one paragraph

Article in Science advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Anne-Laure Mahul-MellierLaboratory of Molecular and Chemical Biology of Neurodegeneration, Institute of Bioengineering (IBI), Ecole Polytechnique Fédérale de Lausanne (EPFL), 1015 Lausanne, Switzerland.ORCID 0000-0002-7830-5483
Lukas van den HeuvelLaboratory of Molecular and Chemical Biology of Neurodegeneration, Institute of Bioengineering (IBI), Ecole Polytechnique Fédérale de Lausanne (EPFL), 1015 Lausanne, Switzerland.ORCID 0000-0001-9168-8450
Maxime TeixeiraCHU de Québec Research Center, Axe Neurosciences, Quebec City G1V 4G2, Canada.ORCID 0000-0001-5506-7331
Manel L N BoussoufLaboratory of Molecular and Chemical Biology of Neurodegeneration, Institute of Bioengineering (IBI), Ecole Polytechnique Fédérale de Lausanne (EPFL), 1015 Lausanne, Switzerland.ORCID 0009-0001-2534-2555
Gaspard OudinotLaboratory of Molecular and Chemical Biology of Neurodegeneration, Institute of Bioengineering (IBI), Ecole Polytechnique Fédérale de Lausanne (EPFL), 1015 Lausanne, Switzerland.ORCID 0009-0005-0966-6567
Amélie ThonetLaboratory of Molecular and Chemical Biology of Neurodegeneration, Institute of Bioengineering (IBI), Ecole Polytechnique Fédérale de Lausanne (EPFL), 1015 Lausanne, Switzerland.ORCID 0009-0002-6195-7044
Davide SperiLaboratory of Molecular and Chemical Biology of Neurodegeneration, Institute of Bioengineering (IBI), Ecole Polytechnique Fédérale de Lausanne (EPFL), 1015 Lausanne, Switzerland.ORCID 0009-0007-7264-4752
Yllza JasiqiLaboratory of Molecular and Chemical Biology of Neurodegeneration, Institute of Bioengineering (IBI), Ecole Polytechnique Fédérale de Lausanne (EPFL), 1015 Lausanne, Switzerland.ORCID 0000-0001-9902-2362
Christina UlrichUPDANGELO, IBI and Global Health Institute, EPFL, 1015 Lausanne, Switzerland.
Razan ShetaCHU de Québec Research Center, Axe Neurosciences, Quebec City G1V 4G2, Canada.ORCID 0009-0008-2403-4922
Walid IdiCHU de Québec Research Center, Axe Neurosciences, Quebec City G1V 4G2, Canada.ORCID 0000-0002-9850-0446
Mary CroisierBioEM Core Facility and Technology Platform, EPFL, 1015 Lausanne, Switzerland.
Stéphanie Clerc-RossetBioEM Core Facility and Technology Platform, EPFL, 1015 Lausanne, Switzerland.
Jérôme BlancBioEM Core Facility and Technology Platform, EPFL, 1015 Lausanne, Switzerland.
Graham KnottBioEM Core Facility and Technology Platform, EPFL, 1015 Lausanne, Switzerland.ORCID 0000-0002-2956-9052
Abid OueslatiCHU de Québec Research Center, Axe Neurosciences, Quebec City G1V 4G2, Canada.ORCID 0000-0003-1122-7086
Hilal A LashuelLaboratory of Molecular and Chemical Biology of Neurodegeneration, Institute of Bioengineering (IBI), Ecole Polytechnique Fédérale de Lausanne (EPFL), 1015 Lausanne, Switzerland.ORCID 0000-0001-7682-8320

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The aggregation of alpha-synuclein (aSyn) into intraneuronal inclusions of heterogeneous morphology, known as Lewy bodies (LBs), is a defining hallmark of Parkinson's disease (PD); yet, our understanding of the mechanisms underpinning their formation and heterogeneity remains incomplete. Here, we present a human isogenic induced pluripotent stem cell-derived dopaminergic neuron (iDA) model that faithfully recapitulates the diverse biochemical, morphological, and ultrastructural features of LB neuropathology. The iDA model accurately reproduces the temporal relationships between neuritic and cell-body aSyn pathology and recapitulates the proteome, posttranslational modifications, and morphological diversity of aSyn aggregates found in human PD tissue. Moreover, our work provides critical insight into how different pathways to aSyn fibrillization and the complex interaction between aSyn fibrils and membranous organelles shape the morphological diversity of LB-like inclusions. This model represents a versatile platform to investigate the mechanisms of pathology formation, maturation, and neuronal dysfunction and to develop diagnostics and therapeutics that account for the diversity of aSyn pathology in PD and related synucleinopathies.

Indexed as

Dopaminergic NeuronsInduced Pluripotent Stem CellsLewy BodiesModels, BiologicalParkinson Diseasealpha-SynucleinHumansalpha-Synuclein

Identifiers

PMID42430493
PMCPMC13353426

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.